39-17-412 - Controlled substances in Schedule IV.
39-17-412. Controlled substances in Schedule IV.
(a) Schedule IV consists of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section.
(b) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities:
(1) Not more than one (1) milligram of difenoxin (DEA Drug Code No. 9168) and not less than twenty-five (25) micrograms of atropine sulfate per dosage unit; or
(2) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane).
(c) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substance, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1) Alprazolam;
(2) Barbital;
(3) Bromazepam;
(4) Camazepam;
(5) Chloral betaine;
(6) Chloral hydrate;
(7) Chlordiazepoxide;
(8) Clobazam;
(9) Clonazepam;
(10) Clorazepate;
(11) Clotiazepam;
(12) Cloxazolam;
(13) Delorazepam;
(14) Diazepam;
(15) Dichloralphenazone;
(16) Estazolam;
(17) Ethchlorvynol;
(18) Ethinamate;
(19) Ethyl Loflazepate;
(20) Fludiazepam;
(21) Flunitrazepam;
(22) Flurazepam;
(23) Halazepam;
(24) Haloxazolam;
(25) Ketazolam;
(26) Loprazolam;
(27) Lorazepam;
(28) Lormetazepam;
(29) Mebutamate;
(30) Medazepam;
(31) Meprobamate;
(32) Methohexital;
(33) Methylphenobarbital (mephobarbital);
(34) Midazolam;
(35) Nimetazepam;
(36) Nitrazepam;
(37) Nordiazepam;
(38) Oxazepam;
(39) Oxazolam;
(40) Paraldehyde;
(41) Petrichloral;
(42) Phenobarbital;
(43) Pinazepam;
(44) Quazepam;
(45) Prazepam;
(46) Temazepam;
(47) Tetrazepam;
(48) Triazolam;
(49) Zaleplon; or
(50) Zopiclone.
(d) Fenfluramine. Any material, compound, mixture, or preparation that contains any quantity of fenfluramine, including its salts, isomers (whether optical, positional, or geometric), and salts of isomers, whenever the existence of the salts, isomers, and salts of isomers is possible.
(e) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, positional, or geometric), and salts of isomers whenever the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1) Butorphanol, including its optical isomers;
(2) Catha edulis (Khat or Chat) when cathinone is absent but cathine is present;
(3) Diethylpropion;
(4) Fencamfamin;
(5) Fenproporex;
(6) Mazindol;
(7) Mefenorex;
(8) Modafinil;
(9) Pemoline (including organometallic complexes and chelates thereof);
(10) Phentermine;
(11) Pipradol;
(12) SPA ((-)-1-dimethylamino-1, 2-diphenylethane); or
(13) Sibutramine.
(f) Other substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substance, including its salts:
(1) Pentazocine;
(2) [Deleted by 2007 amendment.]
(3) [Deleted by 2007 amendment.]
(4) [Deleted by 2007 amendment.]
(g) Notwithstanding any rule or regulation of the board of medical examiners to the contrary, a licensed physician may prescribe, order, administer, sell, or otherwise distribute the Schedule IV controlled substances fenfluramine, its salts and isomers, and salts of isomers, and phentermine, cited in subsection (d) and subdivision (e)(5), respectively, for any of the substances' currently accepted medical use in treatment in the United States.
[Acts 1989, ch. 591, § 1; 1997, ch. 107, § 2; 1997, ch. 236, § 1; 1997, ch. 445, § 1; 1998, ch. 868, § 1; 2000, ch. 755, § 1; 2007, ch. 298, §§ 11-13.]